Clinical Trial Update: Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss [NA]

View source ↗

Summary

The update reports on the efficacy of pegylated interferon alfa-2a in Hepatitis B patients treated with entecavir who have not achieved HBeAg loss.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ENTECAVIR (ENTECAVIR)
• Peg-interferon α-2a (pegylated interferon alfa-2a)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatitis B | NA | Status: UNKNOWN